SCHEMBL21241840

SCHEMBL21241840

O=C(NC(CCc1ccccc1)C(=O)Nc1nc(-c2ccccc2)cs1)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.59
ELOVL1 Q9BW60 1/20 0.57
PARP1 P09874 1/20 0.56
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
NPC1 O15118 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241769 1.00 SCD (0.59) SCDELOVL1PARP1LMNAKDM4E
SCHEMBL21224489 0.88 SCD (0.60) SCDELOVL1PARP1LMNAKDM4E
SCHEMBL21224491 0.88 SCD (0.60) SCDELOVL1PARP1LMNAKDM4E
SCHEMBL21224153 0.87 SCD (0.59) SCDPARP1LMNAKDM4EALDH1A1
SCHEMBL21224152 0.87 SCD (0.59) SCDPARP1LMNAKDM4EALDH1A1
SCHEMBL22971497 0.86 SCD (0.64) SCDELOVL1PARP1LMNAKDM4E
SCHEMBL22971527 0.86 SCD (0.64) SCDELOVL1PARP1LMNAKDM4E
SCHEMBL21241784 0.86 SCD (0.58) SCDPARP1LMNAKDM4EALDH1A1
SCHEMBL21241916 0.86 SCD (0.58) SCDPARP1LMNAKDM4EALDH1A1
SCHEMBL22971607 0.85 SCD (0.62) SCDELOVL1PARP1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SCD 3594/4885ELOVL1 2017/4885PARP1 491/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SCD 3594/4885ELOVL1 2017/4885PARP1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.